AOTMiT: Transparency Council on depression, infertility and coronavirus, among others

The agenda includes:

Preparation of an opinion for the amendment of the conditions required for the electrophysiology laboratory under the benefit "Comprehensive care after myocardial infarction".

Preparation of positions on drug evaluation:

1. Oramorph (morphini sulfas) for the following indication: treatment of patients with malignant tumors, chronic postherpetic neuralgia, multiple local pain syndrome type I - reflex sympathetic dystrophy and type II - causalgia.
2. Paxlovid (nirmatrelvirum; itonavirum) for the indication: treatment of coronavirus 2019 (COVID-19) disease (confirmed by a registered PCR or antigen test) in symptomatic (initiation of treatment within 5 days of symptom onset) adult patients who do not require oxygen therapy (resulting from COVID-19) and who are at increased risk of progression to severe COVID-19, defined as:
3. The presence of at least 3 risk factors among the following:age ≥ 65 years;obesity (BMI ≥ 35 kg/m2);chronic lung disease (daily therapy required for asthma);cardiovascular disease: myocardial infarction, stroke, transient ischemic episode (TIA), heart failure, angina, cardiomyopathy, status after: coronary artery bypass grafting, percutaneous coronary intervention, carotid endarterectomy, aortic bypass grafting; diabetes; chronic kidney disease; or
4. A diagnosis of immunodeficiency or chronic use of immunosuppressants: systemic corticosteroids at a dose equivalent to ≥ 20 mg of prednisone per day for at least 14 consecutive days within the last 30 days; biologic drugs, immunomodulatory drugs or anticancer drugs within the last 90 days; or
5. active malignant neoplasm.
6. Ryeqo (relugolixum; estradiolum; norethisterone acetate) for the indication: treatment of moderate to severe symptoms of uterine myomas in adult women of reproductive age.

Preparation of opinions on draft health policy programs of local government units:

• "Health policy program on prevention of depressive disorders for people over 60 from the Mazovian province."
• "Subsidy for infertility treatment by in vitro fertilization for residents of the city of Biala Podlaska".

Source: AOTMiT